JP2014509595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509595A5 JP2014509595A5 JP2013558234A JP2013558234A JP2014509595A5 JP 2014509595 A5 JP2014509595 A5 JP 2014509595A5 JP 2013558234 A JP2013558234 A JP 2013558234A JP 2013558234 A JP2013558234 A JP 2013558234A JP 2014509595 A5 JP2014509595 A5 JP 2014509595A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- immunotherapeutic composition
- brachyury
- yeast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 61
- 230000001024 immunotherapeutic effect Effects 0.000 claims 56
- 239000000427 antigen Substances 0.000 claims 35
- 102000036639 antigens Human genes 0.000 claims 35
- 108091007433 antigens Proteins 0.000 claims 35
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 29
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 29
- 206010028980 Neoplasm Diseases 0.000 claims 23
- 201000011510 cancer Diseases 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 11
- 108020001507 fusion proteins Proteins 0.000 claims 7
- 102000037865 fusion proteins Human genes 0.000 claims 7
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 claims 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 4
- 102100034256 Mucin-1 Human genes 0.000 claims 3
- 108010008707 Mucin-1 Proteins 0.000 claims 3
- 208000003837 Second Primary Neoplasms Diseases 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 238000011275 oncology therapy Methods 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 102000006108 VHL Human genes 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 101150046474 Vhl gene Proteins 0.000 claims 2
- 102000001307 androgen receptors Human genes 0.000 claims 2
- 108010080146 androgen receptors Proteins 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 108700037122 EWS-FLI fusion Proteins 0.000 claims 1
- 101710147220 Ent-copalyl diphosphate synthase, chloroplastic Proteins 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 241000578472 Human endogenous retrovirus H Species 0.000 claims 1
- 241000192019 Human endogenous retrovirus K Species 0.000 claims 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 claims 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 claims 1
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims 1
- 101150094640 Siae gene Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100030306 TBC1 domain family member 9 Human genes 0.000 claims 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims 1
- 102000018252 Tumor Protein p73 Human genes 0.000 claims 1
- 108010091356 Tumor Protein p73 Proteins 0.000 claims 1
- 102000003425 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 230000003698 anagen phase Effects 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- ONCZDRURRATYFI-QTCHDTBASA-N methyl (2z)-2-methoxyimino-2-[2-[[(e)-1-[3-(trifluoromethyl)phenyl]ethylideneamino]oxymethyl]phenyl]acetate Chemical compound CO\N=C(/C(=O)OC)C1=CC=CC=C1CO\N=C(/C)C1=CC=CC(C(F)(F)F)=C1 ONCZDRURRATYFI-QTCHDTBASA-N 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 208000015768 polyposis Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161453656P | 2011-03-17 | 2011-03-17 | |
| US61/453,656 | 2011-03-17 | ||
| PCT/US2012/029636 WO2012125998A1 (en) | 2011-03-17 | 2012-03-19 | Yeast-brachyury immunotherapeutic compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016249307A Division JP6309607B2 (ja) | 2011-03-17 | 2016-12-22 | 酵母−ブラキュリ免疫治療組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014509595A JP2014509595A (ja) | 2014-04-21 |
| JP2014509595A5 true JP2014509595A5 (cg-RX-API-DMAC7.html) | 2015-04-30 |
| JP6068368B2 JP6068368B2 (ja) | 2017-01-25 |
Family
ID=46831122
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013558234A Active JP6068368B2 (ja) | 2011-03-17 | 2012-03-19 | 酵母−ブラキュリ免疫治療組成物 |
| JP2016249307A Active JP6309607B2 (ja) | 2011-03-17 | 2016-12-22 | 酵母−ブラキュリ免疫治療組成物 |
| JP2018046148A Active JP6580733B2 (ja) | 2011-03-17 | 2018-03-14 | 酵母−ブラキュリ免疫治療組成物 |
| JP2019155138A Pending JP2019199484A (ja) | 2011-03-17 | 2019-08-28 | 酵母−ブラキュリ免疫治療組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016249307A Active JP6309607B2 (ja) | 2011-03-17 | 2016-12-22 | 酵母−ブラキュリ免疫治療組成物 |
| JP2018046148A Active JP6580733B2 (ja) | 2011-03-17 | 2018-03-14 | 酵母−ブラキュリ免疫治療組成物 |
| JP2019155138A Pending JP2019199484A (ja) | 2011-03-17 | 2019-08-28 | 酵母−ブラキュリ免疫治療組成物 |
Country Status (19)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2170384B1 (en) | 2007-07-02 | 2016-04-13 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
| WO2012083302A2 (en) | 2010-12-17 | 2012-06-21 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| MA34956B1 (fr) | 2011-02-12 | 2014-03-01 | Globeimmune Inc | Therapeutique a base de levure pour infection chronique par l'hepatite b |
| BR112013023456B1 (pt) | 2011-03-17 | 2020-11-17 | Globeimmune, Inc. | composições imunoterapêuticas de levedura brachyury, e seus usos |
| EP2720716B1 (en) | 2011-06-14 | 2018-03-21 | Globeimmune, Inc. | Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection |
| JP6122007B2 (ja) | 2011-08-17 | 2017-04-26 | グローブイミューン，インコーポレイテッド | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
| US9653272B2 (en) | 2012-06-26 | 2017-05-16 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
| KR20150132867A (ko) * | 2013-03-19 | 2015-11-26 | 글로브이뮨 | 척색종에 대한 효모-기반의 면역치료 |
| WO2014160747A2 (en) | 2013-03-26 | 2014-10-02 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
| US10226522B2 (en) | 2013-08-30 | 2019-03-12 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of tuberculosis |
| CN106456677B (zh) | 2014-04-11 | 2025-06-03 | 全球免疫股份有限公司 | 基于酵母的免疫疗法和i型干扰素敏感性 |
| CN113456812B (zh) | 2015-01-09 | 2024-08-20 | 埃图比克斯公司 | 用于联合免疫治疗的方法和组合物 |
| US11149087B2 (en) | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| US11065313B2 (en) * | 2015-08-03 | 2021-07-20 | Globeimmune, Inc. | Modified yeast-brachyury immunotherapeutic compositions |
| US10550164B2 (en) * | 2015-08-03 | 2020-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and their use |
| JP2019513021A (ja) | 2016-03-24 | 2019-05-23 | ナントセル，インコーポレイテッド | ネオエピトープ提示のための配列の配置および配列 |
| JP6983819B2 (ja) * | 2016-06-03 | 2021-12-17 | エトゥビクス コーポレーション | 前立腺がん関連抗原を使用する腫瘍ワクチン接種用の組成物及び方法 |
| US11571446B2 (en) | 2016-11-18 | 2023-02-07 | Sanford Bumham Prebys Medical Discovery Institute | Gut microbiota and treatment of cancer |
| AU2018258119B2 (en) | 2017-04-24 | 2021-04-01 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
| JP7062754B2 (ja) * | 2017-08-15 | 2022-05-06 | ナントセル，インコーポレイテッド | ｈａＮＫセツキシマブ併用及び方法 |
| CN119818663A (zh) | 2018-05-15 | 2025-04-15 | 全球免疫公司 | 用于诱导细胞免疫应答的重组酵母裂解物 |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| US12245355B2 (en) | 2021-02-19 | 2025-03-04 | Mevion Medical Systems, Inc. | Gantry for a particle therapy system |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1036329A (en) | 1908-11-19 | 1912-08-20 | Edison Inc Thomas A | Phonograph-reproducer. |
| FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
| US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
| IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
| US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| AU1951001A (en) | 2000-04-06 | 2001-09-17 | Panacea Pharm Llc | Microbial delivery system |
| AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| CN1938044B (zh) | 2002-12-16 | 2011-12-28 | 全球免疫股份有限公司 | 用于免疫治疗的基于酵母的疫苗 |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| WO2007008780A2 (en) * | 2005-07-11 | 2007-01-18 | Globeimmune, Inc. | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| KR101492524B1 (ko) * | 2006-02-02 | 2015-02-12 | 글로브이뮨 | 면역 반응 유도를 위한 효모-기반 백신 |
| MX2008012392A (es) | 2006-03-27 | 2008-12-17 | Globeimmune Inc | Mutacion de ras, y composiciones y metodos relacionados con la misma. |
| SG171577A1 (en) * | 2007-02-02 | 2011-06-29 | Globeimmune Inc | Methods for producing yeast-based vaccines |
| US8188214B2 (en) | 2007-02-28 | 2012-05-29 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
| KR20100015661A (ko) | 2007-03-19 | 2010-02-12 | 글로브이뮨 | 암의 표적 치료법의 돌연변이성 이탈의 표적 절제를 위한 조성물 및 방법 |
| WO2009042645A2 (en) | 2007-09-24 | 2009-04-02 | President And Fellows Of Harvard College | The use of mice predisposed to develop ulcerative colitis and colon cancer to develop metabolic profiles associated with same |
| WO2010033841A1 (en) | 2008-09-19 | 2010-03-25 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis c virus infection |
| WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
| ES2660597T3 (es) * | 2009-04-17 | 2018-03-23 | Globeimmune, Inc. | Composiciones inmunoterápicas de combinación contra el cáncer y métodos |
| CA2774326C (en) | 2009-09-14 | 2023-11-07 | Donald Bellgrau | Modulation of yeast-based immunotherapy products and responses |
| US20130121964A1 (en) | 2010-03-14 | 2013-05-16 | Globeimmune, Inc. | Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy |
| WO2012019127A2 (en) * | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
| WO2012083302A2 (en) | 2010-12-17 | 2012-06-21 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| MA34956B1 (fr) | 2011-02-12 | 2014-03-01 | Globeimmune Inc | Therapeutique a base de levure pour infection chronique par l'hepatite b |
| BR112013023456B1 (pt) | 2011-03-17 | 2020-11-17 | Globeimmune, Inc. | composições imunoterapêuticas de levedura brachyury, e seus usos |
| EP2720716B1 (en) | 2011-06-14 | 2018-03-21 | Globeimmune, Inc. | Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection |
| JP6122007B2 (ja) | 2011-08-17 | 2017-04-26 | グローブイミューン，インコーポレイテッド | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
-
2012
- 2012-03-19 BR BR112013023456-3A patent/BR112013023456B1/pt active IP Right Grant
- 2012-03-19 RU RU2017116350A patent/RU2690180C2/ru active
- 2012-03-19 DK DK12757534.8T patent/DK2685995T3/en active
- 2012-03-19 CN CN201280023412.6A patent/CN103648513B/zh active Active
- 2012-03-19 EP EP17154014.9A patent/EP3238731B1/en active Active
- 2012-03-19 WO PCT/US2012/029636 patent/WO2012125998A1/en not_active Ceased
- 2012-03-19 SG SG10201601913RA patent/SG10201601913RA/en unknown
- 2012-03-19 AU AU2012228937A patent/AU2012228937B2/en active Active
- 2012-03-19 CA CA2835475A patent/CA2835475C/en active Active
- 2012-03-19 MX MX2013010475A patent/MX350661B/es active IP Right Grant
- 2012-03-19 SG SG2013068176A patent/SG193396A1/en unknown
- 2012-03-19 JP JP2013558234A patent/JP6068368B2/ja active Active
- 2012-03-19 EP EP12757534.8A patent/EP2685995B1/en active Active
- 2012-03-19 PL PL12757534T patent/PL2685995T3/pl unknown
- 2012-03-19 PT PT127575348T patent/PT2685995T/pt unknown
- 2012-03-19 HU HUE12757534A patent/HUE033491T2/en unknown
- 2012-03-19 RU RU2013146324A patent/RU2619850C2/ru active IP Right Revival
- 2012-03-19 ES ES12757534.8T patent/ES2627979T3/es active Active
- 2012-03-19 KR KR1020137027169A patent/KR102046449B1/ko active Active
-
2013
- 2013-03-14 US US13/803,719 patent/US9198941B2/en active Active
- 2013-09-12 IL IL228421A patent/IL228421B/en active IP Right Grant
-
2015
- 2015-10-29 US US14/926,372 patent/US9623097B2/en active Active
-
2016
- 2016-12-22 JP JP2016249307A patent/JP6309607B2/ja active Active
-
2017
- 2017-02-02 AU AU2017200715A patent/AU2017200715B2/en active Active
- 2017-03-09 US US15/454,176 patent/US10363294B2/en active Active
-
2018
- 2018-03-14 JP JP2018046148A patent/JP6580733B2/ja active Active
- 2018-04-19 HK HK18105126.6A patent/HK1245649A1/en unknown
- 2018-04-30 AU AU2018202972A patent/AU2018202972B2/en active Active
-
2019
- 2019-04-19 US US16/389,235 patent/US11944673B2/en active Active
- 2019-08-28 JP JP2019155138A patent/JP2019199484A/ja active Pending
-
2020
- 2020-12-21 US US17/129,633 patent/US11938175B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509595A5 (cg-RX-API-DMAC7.html) | ||
| RU2013146324A (ru) | Иммунотерапевтические композиции на основе дрожжей с brachyury | |
| Zhang et al. | Personalized cancer vaccines: Targeting the cancer mutanome | |
| JP2012524075A5 (cg-RX-API-DMAC7.html) | ||
| Kumai et al. | Cancer immunotherapy: moving forward with peptide T cell vaccines | |
| RU2014109741A (ru) | Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения | |
| Perez et al. | Active immunotherapy for non-small-cell lung cancer: moving toward a reality | |
| IL294183A (en) | shared neoantigens | |
| CN110621334A (zh) | 个性化免疫原性肽鉴定平台 | |
| JP2018501243A (ja) | 組み換え型リステリア菌株を用いた併用療法 | |
| NZ721908A (en) | Combination therapy with neoantigen vaccine | |
| JP2019512020A5 (cg-RX-API-DMAC7.html) | ||
| JP2018522041A5 (cg-RX-API-DMAC7.html) | ||
| Baratta | Glioblastoma is ‘hot’for personalized vaccines | |
| Kameshima et al. | Immunogenic enhancement and clinical effect by type‐I interferon of anti‐apoptotic protein, survivin‐derived peptide vaccine, in advanced colorectal cancer patients | |
| EP4357356A3 (en) | Antigenic peptides for prevention and treatment of b-cell malignancy | |
| JP2020511139A5 (cg-RX-API-DMAC7.html) | ||
| RU2019132253A (ru) | Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака | |
| He et al. | Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer | |
| Chen et al. | The current therapeutic cancer vaccines landscape in non‐small cell lung cancer | |
| Izzi et al. | Poxvirus-based vaccines for cancer immunotherapy: New insights from combined cytokines/co-stimulatory molecules delivery and “uncommon” strains | |
| Suzuki et al. | Current status of vaccine immunotherapy for gastrointestinal cancers | |
| JP2020507332A5 (cg-RX-API-DMAC7.html) | ||
| Morse et al. | Current immunotherapeutic strategies in colon cancer | |
| Mohapatra et al. | Cancer Vaccines: Types, Mechanisms, and Recent Developments |